ArticleRespirology case reports2018
Management of rifampicin mono-resistant tuberculosis in Queensland, Australia: a retrospective case series.
Article in Respirology case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Genomic insights into low-level rifampicin resistance mediated by borderlineMicrobiology spectrum · 2026Article
- A cartridge-based assay for improved detection of multidrug-resistantJournal of clinical microbiology · 2026Article
- Phenotypic drug resistance and genome sequencing based identified mutations linked to resistance in Mycobacterium tuberculosis isolated from extrapulmonary clinical specimens.Scientific reports · 2026Article
- Rifampin Mono-Resistant Tuberculosis in New York City, 2010-2021: A Retrospective Case Series.Open forum infectious diseases · 2023Article
- Prevalence and outcome of isoniazid-monoresistant tuberculosis at a university hospital in Saudi Arabia.Saudi medical journal · 2021Article
- Low-Level Rifampin Resistance andJournal of clinical microbiology · 2021Article
- Management of rifampicin mono-resistant tuberculosis in Queensland, Australia: a retrospective case series.Respirology case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rifampicin mono-resistant tuberculosis (RMR-TB) is rare worldwide; however, it is associated with poor treatment outcomes. Evidence to guide the treatment of RMR-TB is lacking. International guidelines have recently changed and now recommend that RMR-TB should be managed with multi-drug-resistant tuberculosis (MDR-TB) regimens. This report is a retrospective review of all cases of RMR-TB in Queensland, Australia, from 2000 to 2016 to assess treatment outcomes and regimens used. Twelve cases of RMR-TB were diagnosed, with seven patients completing treatment in Queensland. This study confirms that RMR-TB is rare in Queensland. Generally extended regimens with first-line agents +/- a fluoroquinolone were used, and all patients who completed treatment in Queensland had successful outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.